Semaglutide, a common ingredient in GLP-1 weight-loss medications, is associated with lower risks of worsening mental disorders, according to a new study.
The research, published in The Lancet Psychiatry, found that people following a GLP-1 treatment for diabetes and obesity had a lower need for hospital care and medical leave due to psychiatric reasons.
